Desoxypipradrol
Desoxypipradrol is a benzylpiperidine-based stimulant structurally related to methylphenidate and pipradrol. Developed by Ciba in the 1950s for conditions such as narcolepsy and ADHD, it was ultimately abandoned in favor of methylphenidate. It acts as a norepinephrine-dopamine reuptake inhibitor and is distinguished by its exceptionally long duration of action, a consequence of its high lipophilicity which renders it resistant to metabolic breakdown. It resurfaced as a recreational substance in the late 2000s.
Contents
Dosage & Duration
Dosage
Extremely potent; onset highly variable (15-240 minutes reported). Heavy doses associated with severe prolonged agitation, paranoia, and hallucinations.
Duration
Subjective Effects
Desoxypipradrol produces a relatively standard stimulant experience — euphoria, energy, alertness, and heightened sociability — set apart from comparable drugs by its extreme duration. Effects typically persist for at least 24 hours and frequently up to 48, with overdoses producing symptoms lasting three to four days or longer. Its high potency and history of mislabeled sale contribute to elevated rates of adverse reactions, including anxiety, chest pain, tachycardia, and prolonged agitation that has in severe cases lasted up to five days and required physical restraint.
Physical
The body load is that of a potent, exceptionally long-acting stimulant: wakefulness, decreased appetite, sweating, teeth grinding, and a racing heart. Chest pain and myoclonic muscle spasms or twitches have been reported at relatively high rates.
Stimulation
Stimulation is pronounced and exceptionally long-lasting, routinely spanning one to two days from a single dose.
Uncomfortable
Cognitive
The headspace is energetic and talkative, with mood lift and increased sociability giving way at higher exposures to anxiety, moodiness, aggressiveness, and paranoia. Prolonged agitation is a hallmark of its adverse presentations.
Emotional
Positive mood effects can shift into irritability, anxiety, and paranoia, particularly as use extends across its very long duration.
Social
Visual
Auditory
Reagent Testing
Loading reagent data
Pharmacology
Pharmacodynamics
Desoxypipradrol acts primarily as a norepinephrine-dopamine reuptake inhibitor (NDRI), blocking the reuptake of both dopamine and norepinephrine at their respective transporters. It may also promote dopamine release in certain brain regions. It is notable for its exceptionally high potency relative to structurally related piperidines such as pipradrol and methylphenidate.
Pharmacokinetics
Desoxypipradrol is a highly lipophilic molecule that lacks the polar functional groups typically targeted by metabolic enzymes. Unlike methylphenidate, which possesses an easily cleaved methyl-ester moiety, and pipradrol, which has a hydroxyl group that can be conjugated (e.g. with glucuronide) to facilitate excretion, desoxypipradrol has no readily metabolizable groups. This confers an extremely long elimination half-life compared to most stimulants.
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Tolerance
Dopaminergic stimulants
Harm Potential
Addiction & Dependence
Psychological
HighHigh abuse potential with significant risk of psychological dependence. Compulsive redosing is commonly reported due to the subtle nature of stimulation, leading users to consume dangerous amounts. Addiction develops at a higher rate than with most other stimulants.
Physical
LowPhysical dependence can develop with chronic use. Cravings and withdrawal effects including anxiety, depression, cognitive fatigue, and irritability may occur upon cessation.
Toxicity
Chronic abuse or overdose can cause prolonged neurotoxic effects including severe agitation lasting up to 5 days and myoclonus; long-term heavy use may lead to persistent dopamine receptor downregulation.
Chest pain and tachycardia have been reported at relatively high rates; however, overall cardiovascular stimulation at typical doses may be milder than with many other stimulants.
Psychosis Risk
Desoxypipradrol triggers psychosis at a significantly higher rate than other stimulants, with an uncommonly low threshold. Both chronic abuse and single-exposure overdose can induce psychotic states. Symptoms include auditory and visual hallucinations, paranoid delusions, mania, grandiosity, severe confusion, increased aggression, and urges toward self-harm. Psychotic episodes may persist for up to 5 days after drug use.
History & Culture
Development and Initial Research
Desoxypipradrol was developed by the pharmaceutical company Ciba (now Novartis) during the 1950s. The compound was initially investigated for therapeutic applications including the treatment of narcolepsy and attention deficit hyperactivity disorder, and was marketed in Germany under the trade name…
Legality
By Country
References
Source Pages
Further Reading
2-DPMP Substance Summary
Baselt (2014) - Disposition of Toxic Drugs and Chemicals in Man- Corkery et al. (2012) - 2-DPMP and D2PM: A Preliminary Review
Ferris & Tang (1979) - Comparison of Isomers of Amphetamine, Methylphenidate and Deoxypipradrol- Schifano et al. (2012) - Use and Acute Toxicity of D2PM and 2-DPMP
Talk to Frank: 2-DPMP
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Desoxypipradrol article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.